Antivenin Latrodectus Mactans (antivenin,Latrodectus mactans)
Injection Vial (Ea)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Antivenin (Latrodectus mactans) (equine) is a preparation of equine immunoglobulins capable of neutralizing venom toxins of black widow spiders (Latrodectus mactans).
Antivenin (Latrodectus mactans) (equine) is used in the treatment of symptoms resulting from bites inflicted by the black widow spider (Latrodectus mactans). When indicated, early use of the antivenin is emphasized for prompt relief. However, delayed administration (up to 90 hours after envenomation) reportedly has accelerated recovery and alleviated manifestations in a patient experiencing a prolonged or refractory course of illness.
Sensitivity testing (skin test or conjunctival test) should be conducted in all individuals prior to administration of antivenin (Latrodectus mactans) (equine). (See Dosage and Administration: Sensitivity Testing and Desensitization.)
Generic name: antivenin,Latrodectus mactans
Therapeutic class: Biologicals
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Antivenin Latrodectus Mactans
Indications
The following indications are listed for Antivenin Latrodectus Mactans:
- Envenomation By Black Widow Spider
Also known as: Black Widow Spider Envenomization, Poisoned Bite Of Black Widow Spider, Poisoning Due To Venom Of Black Widow Spider, Toxic Effect Of Venom From A Black Widow Spider.
Dosing
Dosage of antivenin (Latrodectus mactans) (equine) usually is expressed in terms of the number of vials of the antivenin.
The recommended dosage of antivenin (Latrodectus mactans) (equine) in adults and children is the entire contents of a single reconstituted vial (2.5 mL). Symptoms usually subside in 1-3 hours. A single 1-vial dose of antivenin is adequate for most patients; a second 1-vial dose may be necessary in some patients.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
- No disease contraindications
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Anaphylaxis
- Serum sickness
Rare or Very Rare
- Cramps
Precautions
No enhanced messaging available.
No enhanced messaging available.
Animal reproduction studies have not been performed with antivenin (Latrodectus mactans) (equine). The manufacturer states that it is not known whether antivenin (Latrodectus mactans) (equine) can cause fetal harm when administered to a pregnant woman or can affect fertility, and the antivenin should be used during pregnancy only when clearly needed. Antivenin (Latrodectus mactans) (equine) has been used in pregnant women without unusual adverse effects.
It is not known whether antivenin (Latrodectus mactans) (equine) is distributed into milk. Because many drugs are excreted in human milk, the antivenin should be used with caution in nursing women.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Envenomation by black widow spider | ||
| T63.311A | ICD10CM | Toxic effect of venom of black widow spider, accidental (unintentional), initial encounter |
| T63.312A | ICD10CM | Toxic effect of venom of black widow spider, intentional self-harm, initial encounter |
| T63.313A | ICD10CM | Toxic effect of venom of black widow spider, assault, initial encounter |
| T63.314A | ICD10CM | Toxic effect of venom of black widow spider, undetermined, initial encounter |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.